Morria Biopharmaceuticals Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress

LONDON & NEW YORK--(BUSINESS WIRE)--Jun 15, 2010 - Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4 (n=105) in patients suffering from allergic rhinitis at the 29th EAACI Congress (European Academy of Allergy and Clinical Immunology) in London. The study˜s principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.

Study design: the Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season. The double blind placebo-controlled study consisted of a six-day, twice-daily intranasal administration of placebo or MRX-4 followed by an intranasal dose of allergen on the morning of the seventh day with a clinical follow-up and scoring over the next 24 hours. Blood, urine and pharmacokinetics (PK) analyses were also conducted. A separate single blind placebo controlled intranasal steroid arm was also carried out using a budesonide nasal spray.

Study endpoints: The primary objective of the study was to assess safety by examining usual clinical, physiological and biochemical measures. The secondary end-points of the study were (1) levels of inflammatory mediators (IL-5, IL-13, MCP-1, TNF-alpha, IL-8 and Eotoxin) as well as eosinophils in the nasal lavage and (2) assessment of clinical symptoms of rhinorrhea, nasal itching, sneezing, frontal headache, nasal congestion and ear/palatal itching.

Results: The study achieved its primary and secondary objectives. MRX-4 was well tolerated and safe with treatment emergent adverse events being similar in Control and MRX-4 groups. MRX-4 reduced eosinophil numbers, and levels of IL-5, IL-13, eotaxin, MCP-1 and TNF-alpha in nasal lavage fluid were lower during NAC compared to Control. Subjects treated with MRX-4 recorded fewer clinical symptoms than those in the Control group. In particular, MRX-4 significantly reduced symptoms of nasal congestion and frontal headaches, symptoms associated with the late phase of the allergic response that are responsive to controller treatments like corticosteroids.

This favourable safety profile coupled with supportive preliminary efficacy data provides grounds for optimism that MRX-4 will be a useful addition to the class of controller therapies for allergic rhinitis. “For a first-in-patient study in rhinitis, these are promising results,” said Dr. Eric Bateman. “I look forward to the next clinical study and to further investigating the clinical potential of this drug.”

The study was supported by the Flight Attendants Medical Research Institute (FAMRI).

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel, anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known anti-inflammatory drug target. At the same time, they also enrich the cell surface glycosaminoglycans thereby protecting the cell against inflammatory agents. Morria is determined to become a pivotal player in the anti-inflammatory drug market by developing and commercializing novel drugs for respiratory, dermatology, pulmonary, gastro-intestinal and ophthalmological inflammatory diseases. For more information, please visit http://www.morria.com.

Morria recently announced the launch of an investigator-led Phase II (n=80) in contact dermatitis following a preceding study which demonstrated promising clinical results.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.

Contact: Morria Biopharmaceuticals Plc
Yuval Cohen (PhD), Managing Director - President
Tel: +44 (0)207 152 6341
Fax: +44 (0) 207 152 6342
Email: info@morria.com

 

Posted: June 2010

View comments

Hide
(web3)